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Background: OnabotulinumtoxinA has demonstrated significant benefit in adult focal spasticity. This study reviews
the injection patterns (i.e., muscle distribution, dosing) of onabotulinumtoxinA for treatment of adult spasticity, as
reported in published studies.
Methods: A systematic review of clinical trials and observational studies published between 1990 and 2011
reporting data on muscles injected with onabotulinumtoxinA in adult patients treated for any cause of spasticity.
Results: 28 randomized, 5 nonrandomized, and 37 single-arm studies evaluating 2,163 adult patients were
included. The most frequently injected upper-limb muscles were flexor carpi radialis (64.0% of patients), flexor carpi
ulnaris (59.1%), flexor digitorum superficialis (57.2%), flexor digitorum profundus (52.5%), and biceps brachii (38.8%).
The most frequently injected lower-limb muscles were the gastrocnemius (66.1% of patients), soleus (54.7%), and
tibialis posterior (50.5%). The overall dose range reported was 5–200 U for upper-limb muscles and 10–400 U for
lower-limb muscles.
Conclusions: The reviewed evidence indicates that the muscles most frequently injected with onabotulinumtoxinA
in adults with spasticity were the wrist, elbow, and finger flexors and the ankle plantar flexors. OnabotulinumtoxinA
was injected over a broad range of doses per muscle among the studies included in this review, but individual
practitioners should be mindful of local regulatory approvals and regulations.
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Spasticity, a phenomenon associated with the upper motor
neuron syndrome, was defined by James W. Lance as “a
motor disorder characterized by a velocity-dependent in-
crease in tonic stretch reflex (muscle tone) with exagger-
ated tendon jerks, resulting from hyper-excitability of the
stretch reflex as one component of the upper motor
neuron syndrome” [1].
The causes of spasticity are heterogeneous. While spasti-
city following stroke is common, spasticity can also occur
in adults following traumatic brain injury, multiple scler-
osis, spinal cord injury, and, on some occasions, degene-
rative central nervous system disorders [2,3]. Spasticity
is often classified according to the distribution of body* Correspondence: lnalysnyk@aol.com
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reproduction in any medium, provided the orregions affected, which may be focal, regional, or general-
ized [4,5]. Focal spasticity affects an isolated body part such
as the elbow or foot, whereas regional spasticity can affect
an entire limb and generalized spasticity affects multiple
body areas. Topographical spasticity patterns vary with dif-
ferent etiologies. The distribution of spasticity is important
to identify because it has treatment implications [6].
Spasticity-related muscle dysfunction is characterized
by muscle hyperactivity/hypertonicity, motor weakness,
and, in progressed cases, contracture of adjacent soft tis-
sue [7,8]. Substantial evidence demonstrates that spasticity
has a negative impact on patients, causing impairment
(e.g., pain, pressure sores, contractures), activity limita-
tion, dependence on caregivers, restriction of participa-
tion in social and family life, and decreased overall
quality of life [9-11].
Management of spasticity can vary from patient to pa-
tient, typically is customized to individual patient needs,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and participation of specialists, such as a physiatrist or
neurologist, nurses, physical therapists, caregivers, and the
patients themselves [12]. Numerous treatments are used
to reduce spasticity. Botulinum neurotoxin (BoNT) injec-
tions are employed as a focal antispastic agent, usually as
part of a broader rehabilitation regimen [4]. In the devel-
opment of an overall treatment plan, consideration should
be given to the treatment goals, including the balance be-
tween reduction of spastic hypertonia and preservation of
residual motor strength and function [13].
In the United States, there are four botulinum toxin
products approved for various indications. Three are sero-
type A (onabotulinumtoxinA [BOTOX®, Allergan Inc.,
Irvine, CA, USA]; abobotulinumtoxinA [Dysport®, Ipsen,
Paris, France]; and incobotulinumtoxinA [Xeomin®, Merz
Pharmaceuticals GmbH, Frankfurt, Germany]), and one is
serotype B (rimabotulinumtoxinB [Myobloc®/Neurobloc®,
Solstice Neurosciences, San Francisco, CA, USA]). Each
differs in molecular structure, formulation, and clinical
profile. There is no potency reference standard that is ap-
plicable for BoNTs, and each formulation of BoNT is dif-
ferent. Therefore, the units of activity are specific to each
product and are not interchangeable with those of any
other BoNT [14]. Currently, only onabotulinumtoxinA is
approved by the US Food and Drug Administration for the
treatment of upper-limb spasticity in adults [15].
Although many studies have been published with regard
to the efficacy, safety, and effectiveness of onabotuli-
numtoxinA for the treatment of spasticity, there is no
comprehensive analysis of the literature available that ex-
amines the injection patterns of onabotulinumtoxinA. It is
therefore the aim of this systematic review to summarize
the specific topography of injected muscles, the mean dose
of injections per muscle, and the range of doses among
patients treated with onabotulinumtoxinA for adult spasti-
city. It should be noted that “injection patterns” is a broad
term that can also include regional topography of injec-
tions and techniques for isolating muscles for injection;
for the purposes of this review, the term “injection pat-
terns” refers only to the above-mentioned topics of spe-
cific topography of injected muscles and dosing.
Methods
Literature search
A prospective protocol outlining the methodology of this
systematic review was developed and followed. A literature
search was performed to identify all English-language clin-
ical trials or observational studies (prospective or retro-
spective) of onabotulinumtoxinA injections used for the
treatment of patients with adult spasticity published since
1990. The methods used to perform this review involved
both electronic and manual components, and followed
established “best practice” guidelines for systematic reviewresearch [16,17]. Searches in MEDLINE and EMBASE
were conducted for all studies of BoNT used for treatment
of adult spasticity and published between January 1985
and April 2011 to identify any studies of onabotuli-
numtoxinA. The combination of the following search
terms was used: spastic, spasticity, spasm, hyperreflexia,
hypertonia, hemiplegia, paralysis. For details of the spe-
cific search terms used, please see Additional file 1. The
electronic searches were further supplemented by a man-
ual search of the reference lists of all accepted studies, as
well as the reference lists of recent relevant reviews and
meta-analyses.
Study identification
Animal or in vitro studies, studies performed in pediatric
populations, and studies reporting treatment with BoNT
products other than onabotulinumtoxinA were excluded.
The full-text publications of accepted abstracts were
reviewed to satisfy all of the following inclusion criteria,
regardless of spastic pattern or origin: adult patients
with spasticity, treated with onabotulinumtoxinA, and
available data on which individual muscles in the upper
and/or lower limbs were injected with onabotuli-
numtoxinA. Included studies were not required to re-
port the number of patients injected or dose parameters
for specific muscles, although this data was captured
when reported. The agreement of two investigators was
required to accept or reject any articles during the re-
view process.
Data extraction and synthesis
Data elements of interest from each accepted study were
extracted to a data extraction form. Extracted information
included study-level (e.g., year of publication, geographic
region, and study design), patient-level (e.g., sample size,
mean age, and gender distribution), and treatment-level
(e.g., mean dose and site of onabotulinumtoxinA injection)
characteristics. Whenever possible, subgroup data were
extracted by spasticity diagnosis from studies enrolling pa-
tients with spasticity due to various causes. All injected
muscles were considered as reported, regardless of the
spastic pattern or origin of spasticity in individuals or pa-
tient populations. For studies with patient samples that
also included patients treated with other BTX-A formula-
tions, only patients treated with onabotulinumtoxinA were
considered. One investigator extracted the data from each
study, and a second investigator independently reviewed
the extracted data for completeness and accuracy against
the original study. Efficacy, safety, and patient-reported
outcomes were not assessed in this review and therefore
not captured.
Linked studies, which are multiple studies that report
outcomes from the same patient sample, in part or in total,
were identified during the screening and data extraction
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from the largest, most recent, or most complete report
were extracted. However, relevant data from earlier and
smaller reports were also used if the report presented per-
tinent subgroup data not presented in the larger, more
complete report. Therefore, all linked studies were consid-
ered to be included studies, though each set of linked
studies was only counted as one study to avoid double-
counting patients.
Descriptive statistics were applied to summarize study-,
patient-, and treatment-level data. Information on injected
muscles and corresponding onabotulinumtoxinA doses
was summarized for individual muscles and muscle
groups for upper and lower limbs. Studies reporting on
patients treated with onabotulinumtoxinA for both upper-
and lower-limb spasticity were included in both respective
categories of muscles. Some studies had multiple treat-
ment arms where all patients received onabotulinum-
toxinA (with varying doses, patient characteristics, or
supplemental treatments such as physiotherapy). All tables
include counts of the number of studies (k), the number
of onabotulinumtoxinA treatment arms (t), and the num-
ber of patients (n) that match a given characteristic, as
well as the total number of patients in treatment arms that
reported the characteristic (N). To calculate the fre-
quency of injections in individual muscles, the number
of all patients/limbs treated with onabotulinumtoxinA
in upper limbs or lower limbs, respectively, was used as
a denominator, while the numerator for each muscle
injected was the number of patients/limbs injected in
that particular muscle. Mean doses per muscle were cal-
culated as a mean of all study means, weighted by the
number of patients who received injections into each
muscle in each study. Note that mean dose may not ne-
cessarily account for the full range of doses adminis-
tered, since dose range was reported in more studies
than was mean dose and mean dose could only be tabu-
lated for the subset of studies that explicitly reported it
(see semitendinosus, for example). Descriptive summary
data, including frequencies of muscles injected, are
presented for patients with upper-limb spasticity and
lower-limb spasticity, regardless of spasticity origin.
Categorical outcomes are presented as proportions, and
continuous outcomes are presented using means and
ranges.
Information on injected muscles was also analyzed
separately by the origin of spasticity (i.e., stroke, trau-
matic brain injury, spinal cord injury, or multiple scler-
osis) using the same methods as described above. These
subgroup analyses are presented in Additional files 2, 3,
4 and 5.
Since the focus of this review was not on efficacy and
safety, the risk of bias within individual studies was not
assessed.Results
Study attrition
The entire literature search, including manual bibliog-
raphy checks, identified 2,761 citations, not including
duplicate citations from the various sources. The vast ma-
jority of these citations were rejected during abstract
screening. Corresponding full papers for 135 abstracts
were retrieved for further review and screened against the
protocol-specified inclusion criteria. Of the full papers re-
trieved, 61 were rejected at the full-text review or during
data extraction, leaving 74 publications. Among these 74,
four pairs of linked publications were identified, from in-
stitutions in Turkey [18,19], Italy [20,21], Taiwan [22,23],
and France [24,25]. Since only the most informative study
was counted from each pair of linked publications, a total
of 70 primary studies [2,18,20,23,25-90] pertaining to the
treatment of adult spasticity with onabotulinumtoxinA
were analyzed. The most common rejection reasons were
reviews, not onabotulinumtoxinA treatment, or BoNT for-
mulation not specified. A detailed flow diagram of the
study attrition is presented in Figure 1.
Study characteristics
The majority of the 70 primary studies (comprising
2,163 patients) were conducted in Europe (n = 35) or
North America (n = 18), while nine studies were com-
pleted in Asia and eight in other geographic locations
(Additional file 6). Nearly all included studies (97%) were
published since 1995. There were 28 randomized clinical
trials, five nonrandomized clinical trials, and 37 single-
arm, uncontrolled case series. Sixty-seven studies (96%)
were conducted prospectively. Most studies (n = 33)
reported only treatment of upper-limb spasticity, 11
studies reported treatment of both upper- and lower-
limb spasticity, and 26 studies evaluated patients with
lower-limb spasticity. In total, data on upper-limb spasti-
city was presented in 44 studies comprising 1,670 pa-
tients, of which 788 (47.1%) had frequency data reported
for onabotulinumtoxinA injections in upper-limb mus-
cles. Data on lower-limb spasticity was reported in 37
studies comprising 1,347 patients, of which 602 (44.7%)
had frequency data reported for onabotulinumtoxinA in-
jections in lower-limb muscles. Among the 70 studies
(92 treatment arms), the frequency of injections into in-
dividual muscles was reported in 55 studies (77 treat-
ment arms), and mean dose per injected muscle was
reported in 46 studies (63 treatment arms).
Baseline patient characteristics
Table 1 presents the summary of baseline characteristics
of adult patients treated with onabotulinumtoxinA for
upper- or lower-limb spasticity. Among the large majority
of studies reporting gender distribution of enrolled pa-
























2,761 abstracts identified 
from literature searches
2,626 abstracts excluded
61 papers excluded:  
25 Reviews, case reports
11 BTX-A not specified
12 Not BOTOX treatment
9 Injected muscles not reported 
4 Pediatric population
135 full-text papers retrieved and reviewed
74 publications in dataset:   
70 Primary studies
4 Linked publications
Figure 1 Flow diagram of study attrition.
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most commonly reported cause of upper- and lower-limb
spasticity (66.2% and 62.1%, respectively), while strokes or
traumatic brain injuries were combined in several studies
as the cause of spasticity in 6.4% (upper limb) and 5.2%Table 1 Baseline patient characteristics
Characteristic Upper-limb spasticity
k t n/N Fre
Total 44 59* 1,670
Gender 36 47 1,464
Male 36 47 883/1,464
Female 36 47 581/1,464
Spasticity origin 44 59 1,670
Stroke only 24 31 1,105/1,670
Stroke/Traumatic brain injury 6 8 107/1,670
Traumatic brain injury only 1 2 21/1,670
Multiple sclerosis 2 3 43/1,670
Spinal cord injury 1 1 28/1,670
Mixed/Other 10 14 366/1,670
k t Mean Ran
Age (years) 39 53 51.7
Time since onset (months) 31 43 46.9
k = Number of studies, t = Number of treatment arms, n = Number of patients with
characteristic. *The 44 studies that reported on patients with upper-limb spasticity
these arms consisted of at least 1 patient with upper-limb spasticity, as shown in Ta(lower limb) of patients. Traumatic brain injury, multiple
sclerosis, and spinal cord injuries were reported to be the
cause of spasticity in approximately 7% of all patients
combined, while in 22.7% of all patients various causes of
spasticity were reported. The mean age of patients withLower-limb spasticity
quency (%) k t n/N Frequency (%)
– 37 47 1,347 –
100.0 31 40 1,200 100.0
60.3 31 40 699/1,200 58.3
39.7 31 39 501/1,200 41.8
100.0 37 47 1,347 100.0
66.2 16 21 837/1,347 62.1
6.4 3 3 70/1,347 5.2
1.3 1 1 7/1,347 0.5
2.6 5 6 80/1,347 5.9
1.7 1 2 36/1,347 2.7
21.9 11 14 317/1,347 23.5
ge of means k t Mean Range of means
26 – 66.3 35 45 49.9 26 – 66.3
4.7 – 120 26 34 53.6 0.35 – 218.4
this characteristic, N = Total number of patients in treatment arms reporting
had a total of 59 onabotulinumtoxinA treatment arms; however, only 58 of
ble 2.
able 2 Dose range, muscle distribution, and mean dose of onabotulinumtoxinA injections in upper limbs
uscles All studies (44 studies,
58 treatment arms)
Studies reporting number of patients injected
(33 studies, 46 treatment arms)
Studies reporting mean dose
(26 studies, 39 treatment arms)
k t Dose range (U) k t n/N Frequency (%) k t n Mean dose (U)
houlder
fraspinatus 2 2 60 2 2 18/788 2.3 1 1 2 60.0
houlder adductors** 1 1 30–100 1 1 8/788 1.0 1 1 8 55.6
eltoid 1 1 NR 1 1 1/788 0.1 0 0 0 NR
atissimus dorsi† 1 1 50–100 1 1 14/788 1.8 1 1 14 66.1
evator scapulae 1 1 NR 1 1 1/788 0.1 0 0 0 NR
araspinous 1 1 100 1 1 1/788 0.1 1 1 1 100.0
ectoralis 7 7 30–100 5 5 39/788 4.9 3 3 22 67.3
homboid 1 1 50 1 1 8/788 1.0 1 1 8 50.0
ternocleidomastoid 1 1 NR 1 1 2/788 0.3 0 0 0 NR
ubscapularis 2 2 100 2 2 26/788 3.3 1 1 10 100.0
eres major 1 1 40 1 1 1/788 0.1 1 1 1 40.0
rapezius 2 2 60 2 2 3/788 0.4 1 1 1 60.0
riceps brachii 5 6 50–100 4 4 10/788 1.3 3 3 9 73.6
orearm
xtensor carpi radialis 3 4 5–50 3 4 6/788 0.8 2 3 4 17.5
xtensor carpi ulnaris 1 2 5–10 1 2 3/788 0.4 1 2 3 6.7
xtensor digitorum 1 1 NR 1 1 1/788 0.1 0 0 0 NR
ronator quadrates 2 2 25 1 1 1/788 0.1 0 0 0 NR
ronator teres 14 16 10–90 10 11 96/788 12.2 6 7 65 33.3
upinator 1 1 5 1 1 1/788 0.1 1 1 1 5.0
lbow flexors
iceps brachii* 30 40 25–200 19 27 306/788 38.8 16 24 263 95.4
rachialis 10 12 20–100 4 4 27/788 3.4 1 1 1 60.0
rachioradialis 17 20 15–200 9 11 104/788 13.2 7 9 75 41.1
rist flexors
lexor carpi radialis* 34 45 5–100 24 34 504/788 64.0 18 28 433 49.0
lexor carpi ulnaris* 34 45 5–100 23 33 466/788 59.1 18 28 420 46.7
almaris longus 3 3 20–25 2 2 8/788 1.0 1 1 4 23.8
rist flexors‡ 1 1 50–120 1 1 20/788 2.5 1 1 20 72.8
inger flexors
inger flexors§ 1 1 30–160 1 1 20/788 2.5 1 1 20 97.8
lexor digitorum profundus* 31 39 5–120 20 27 414/788 52.5 16 23 361 42.0
lexor digitorum superficialis* 31 40 5–150 20 28 451/788 57.2 16 24 386 50.3
orearm finger flexor 1 1 80 1 1 5/788 0.6 1 1 5 80.0
terossei volares 1 1 10–15 1 1 4/788 0.5 1 1 4 11.3
humb
dductor pollicis 7 8 10–20 5 6 102/788 12.9 3 4 93 18.9
lexor pollicis brevis 1 1 NR 1 1 2/788 0.3 0 0 0 NR
lexor pollicis longus 20 24 10–35 11 13 161/788 20.4 7 9 132 19.0
umbricals 3 4 30 2 2 4/788 0.5 1 1 1 30.0












































Table 2 Dose range, muscle distribution, and mean dose of onabotulinumtoxinA injections in upper limbs
Muscles All studies (44 studies,
58 treatment arms)
Studies reporting number of patients injected
(33 studies, 46 treatment arms)
Studies reporting mean dose
(26 studies, 39 treatment arms)
k t Dose range (U) k t n/N Frequency (%) k t n Mean dose (U)
Opponens 1 1 10 0 0 NR NR 0 0 0 NR
Opponens pollicis 2 2 NR 1 1 4/788 0.5 0 0 0 NR
Other muscles
Other upper-limb muscles 1 1 NR 0 0 NR NR 0 0 0 NR
Upper-limb flexors 1 1 50–150 0 0 NR NR 0 0 0 NR
*Muscles currently approved in the United States for onabotulinumtoxinA injection.
**Deltoid, pectoralis major.
†Reported as “dorsalis major”.
‡Flexor carpi radialis, palmaris longus, flexor carpi ulnaris.
§Flexor pollicis longus, flexor digitorum profundus, flexor digitorum superficialis.
k = Number of studies, t = Number of treatment arms, n = Number of patients injected with onabotulinumtoxinA, N = Total number of patients in treatment arms
reporting number of patients injected with onabotulinumtoxinA, NR = Not reported, U = Units.
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years for patients with spasticity of the lower limb. The
mean time since disease onset was 46.9 months among
patients with spasticity of the upper limb, compared to
53.6 months for patients with spasticity of the lower limb.
Characteristics of onabotulinumtoxinA injections
Upper-limb muscles
The most frequently injected upper-limb muscles were
wrist, finger, and elbow flexors (Table 2). The frequency of
onabotulinumtoxinA injections among 788 patients with
available data indicates that flexor carpi radialis (64.0% of
patients) and flexor carpi ulnaris (59.1%) were the most
commonly injected muscles, followed by flexor digitorum
superficialis (57.2%), flexor digitorum profundus (52.5%),
biceps brachii (38.8%), and flexor pollicis longus (20.4%).
Other muscles, including those in the shoulder and fore-
arm, were injected less frequently, ranging from 0.1% to
13.2% of patients.
Overall, the doses of onabotulinumtoxinA injected
into upper-limb muscles ranged from 5–200 U among
all extracted studies. The mean dose of onabotuli-
numtoxinA injected into the upper-limb muscles ranged
from 5 U in the wrist supinator muscle of the forearm
to 100 U injected in the paraspinous and subscapularis
muscles of the shoulder. The weighted mean doses varied
within muscle groups, although the overall ranges of mean
doses were similar among the shoulder muscles (range:
40–100 U), elbow flexors (range: 41.1–95.4 U), wrist
flexors (range: 23.8–72.8 U), and finger flexors (range:
11.3–97.8 U). Mean doses injected in the forearm (range:
5.0–33.3 U) and thumb muscles (range: 18.9–30 U) were
smaller, as observed by their respective mean dose ranges.
Lower-limb muscles
Ankle plantar flexors were the most frequently injected
muscles of the lower limb (Table 3). Among 602 patients
injected with onabotulinumtoxinA in lower-limbmuscles, 66.1% were injected in the gastrocnemius mus-
cles. Over half of the patients were injected in the soleus
(54.7%) and the tibialis posterior (50.5%), while 12.5% re-
ceived injections in the flexor digitorum longus. Less
than 10% of patients were injected in other lower-limb
muscles, which ranged from 0.2% in the psoas major to
8.3% in the tibialis anterior.
The overall range of doses of onabotulinumtoxinA
injected into lower-limb muscles varied greatly, from 10–
400 U. Mean doses ranged from 30.0 U in the vastus
medialis to 186.9 U in the rectus femoris. Other higher
mean doses were also reported among hip adductors
(range: 91.7–142.4 U), ankle plantar flexors (range: 56.8–
95.2 U), foot flexors and extensors (range: 50.0–71.9 U),
and knee flexors (range: 34.0–75.0 U). The lowest mean
doses reported among lower-limb muscles were injected in
toe flexors (range: 11.7–57.2 U) and knee extensors (range:
30.0–38.3 U).
Discussion
In this systematic review of the literature, we summarized
publications on onabotulinumtoxinA injections in adult pa-
tients treated for upper- or lower-limb spasticity. Our goal
was to review the injection and dosing patterns reported
from various treatment settings including clinical trials and
real-world practices, as a practical guidance manuscript of
this scope is not currently available in the literature.
Seventy-four studies evaluating a total of 2,163 patients
were included in this review.
The reviewed evidence indicates that studies vary in
terms of geography, study design, sample size, treated pa-
tient population, and onabotulinumtoxinA injection prac-
tices. The heterogeneity of treatment patterns reported in
this review likely reflects real differences in topographical
patterns of spasticity. However, it is probable that physician
preference, individual interpretation of clinical treatment
guidelines, and possibly local health care coverage regula-
tions account for much of the variation reported here.
Table 3 Dose range, muscle distribution, and mean dose of onabotulinumtoxinA injections in lower limbs
Muscles All studies (37 studies, 47
treatment arms)
Studies reporting number of patients
injected (31 studies, 40 treatment arms)
Studies reporting mean dose (24
studies, 29 treatment arms)
k t Dose range (U) k t n/N Frequency (%) k t N Mean dose (U)
Hip adductors
Adductor longus 4 4 50–400 4 4 26/602 4.3 3 3 17 115.9
Adductor magnus 5 5 20–200 5 5 26/602 4.3 4 4 17 142.4
Adductor brevis 3 3 50–100 3 3 12/602 2.0 3 3 12 91.7
Hip adductors 5 6 50–160 3 3 32/602 5.3 0 0 0 NR
Hip flexors
Iliopsoas 2 2 40–100 2 2 5/602 0.8 0 0 0 NR
Psoas major 1 1 NR 1 1 1/602 0.2 0 0 0 NR
Rectus femoris 6 6 30–200 6 6 42/602 7.0 4 4 32 186.9
Knee flexors
Biceps femoris 6 6 30–200 5 5 34/602 5.6 2 2 6 56.7
Hamstrings 1 1 50–200 0 0 NR NR 0 0 0 NR
Knee flexors 1 2 NR 0 0 NR NR 0 0 0 NR
Semimembranosus 8 8 40–200 6 6 41/602 6.8 3 3 4 75.0
Semitendinosus 6 6 30–200 4 4 42/602 7.0 1 1 5 34.0
Knee extensors
Quadriceps 1 1 NR 0 0 NR NR 0 0 0 NR
Vastus intermedius 1 1 NR 1 1 4/602 0.7 0 0 0 NR
Vastus lateralis 4 4 25–60 3 3 4/602 0.7 2 2 3 38.3
Vastus medialis 3 3 30 2 2 4/602 0.7 1 1 1 30.0
Ankle plantar flexors
Gastrocnemius 31 36 20–320 26 31 398/602 66.1 16 19 246 88.2
Gastrocnemius lateralis 13 14 50–200 12 13 164/602 27.2 9 9 130 86.7
Gastrocnemius medialis 13 14 50–200 12 13 165/602 27.4 9 9 131 86.8
Soleus 25 28 40–240 21 24 329/602 54.7 14 16 233 95.2
Tibialis anterior 7 7 30–150 5 5 50/602 8.3 2 2 37 56.8
Tibialis posterior 24 29 20–200 18 23 304/602 50.5 11 15 218 80.7
Foot flexors/extensors
Extensor hallucis longus 6 6 25–100 5 5 22/602 3.7 4 4 20 71.9
Flexor hallucis longus 7 7 15–95 7 7 33/602 5.5 4 4 22 50.9
Foot flexors 1 2 NR 0 0 NR NR 0 0 0 NR
Small foot flexors 1 1 50 1 1 5/602 0.8 1 1 5 50.0
Toe flexors
Flexor digitorum longus 10 12 20–125 10 12 75/602 12.5 6 8 50 57.2
Flexor digitorum brevis 6 8 20–100 5 7 25/602 4.2 3 5 18 54.4
Flexor hallucis brevis 2 2 10–15 2 2 3/602 0.5 2 2 3 11.7
k = Number of studies, t = Number of treatment arms, n = Number of patients injected with onabotulinumtoxinA, N = Total number of patients in treatment arms
reporting number of patients injected with onabotulinumtoxinA, NR = Not reported, U = Units.
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among patients with spasticity from different etiologies (see
Additional files 3, 4, 5 and 6).
In the United States, onabotulinumtoxinA is currently
indicated for the treatment of upper-limb spasticity inadult patients to reduce the severity of increased muscle
tone in elbow flexors (biceps), wrist flexors (flexor carpi
radialis and flexor carpi ulnaris), and finger flexors (flexor
digitorum profundus and flexor digitorum sublimis). In
the reviewed studies, these muscles appear to be
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studies, other upper-limb muscles were also injected,
among which the brachialis, brachioradialis, pronator
teres, and flexor pollicis longus were most often
reported. Among lower-limb muscles, ankle plantar
flexors (gastrocnemius, soleus, and tibialis posterior)
were most frequently injected. Other lower-limb muscles
treated with onabotulinumtoxinA included hip adductors,
hip flexors, knee flexors, knee extensors, foot flexors, and
toe flexors. Doses of onabotulinumtoxinA varied depend-
ing on muscle size, location of injection, severity of spasti-
city, and whether the injection was the first treatment or
was performed taking into account the patients’ responses
to previous treatment.
As with any systematic literature review, there are sev-
eral limitations that should be noted. First, it is import-
ant to recognize that not all studies reported detailed
information on onabotulinumtoxinA injections. Some
only listed muscle groups, others specified individual
muscles but did not provide patient counts for injected
muscles, and many studies did not report muscle data
and thus were excluded from this review. In addition,
onabotulinumtoxinA dose information was not reported
consistently across all included studies, and thus the es-
timates of mean dose do not necessarily represent the
full range of doses injected in specific muscles. This po-
tentially reduces the accuracy of estimates of the fre-
quency of muscle injection. Second, our findings might
be biased by the results from clinical trials, where pa-
tients had onabotulinumtoxinA injected into pres-
pecified muscles at specified doses. This may not
accurately reflect onabotulinumtoxinA treatment prac-
tices in adult patients with spasticity in “real life”. The
various aims and scopes of the studies included in this
review may have biased the dosage of onabotuli-
numtoxinA administered in each included study. How-
ever, these studies were included because the injection
site and/or dosage of onabotulinumtoxinA was discussed
in each and the objective of this review was to sum-
marize data on the dose, frequency, and location of
intramuscular injections published in the literature, not
to review associated efficacy and safety outcomes.
Nevertheless, this literature review indicates that ona-
botulinumtoxinA is well studied for the treatment of
adult spasticity of the upper and lower limbs.
Conclusions
Although there is a substantial body of published literature
on onabotulinumtoxinA in adult spasticity, including sys-
tematic reviews and meta-analyses, no prior study, to our
knowledge, has systematically summarized injection pat-
terns. This review provides additional information for phy-
sicians on varying muscle injection distributions and
dosing practices of onabotulinumtoxinA injections in adultspasticity, for both on-label and off-label muscles. These
findings indicate that the wrist, elbow, finger flexors, and
ankle plantar flexors were most frequently injected with
onabotulinumtoxinA in adults with spasticity. The overall
dose range of onabotulinumtoxinA injected was 5–200 U
for upper-limb muscles and 10–400 U for lower-limb mus-
cles. As regulatory approvals for onabotulinumtoxinA dif-
fer across countries, the patterns of injection/treatment
presented here are the results of this literature search and
are neither an endorsement for use nor a substitution for
local regulations.
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